|
Post by JHam on Jul 29, 2014 12:48:55 GMT
|
|
|
Post by JHam on Jul 29, 2014 12:50:37 GMT
Here's the quick synopsis from SA:
In order to free up capital for the future development of its Lm-LLO cancer immunotherapy, Advaxis (NASDAQ:ADXS) and the University of Pennsylvania restructure their exclusive license agreement. The amended contract eliminates the milestone payment due UPenn at the start of a Phase 3 clinical trial and modifies milestone payments related to regulatory approval. In exchange, UPenn will receive a higher royalty rate on net sales and enhanced milestone payments with global sales reach $250M - 2B.
|
|
|
Post by jckrdu on Jul 29, 2014 13:01:06 GMT
Here's the details from the SEC filing. A $400k milestone payment was eliminated and other terms were restructured so ADXS pays less up front and more on the backend. Not real big news IMO, but who knows what the market will think. _____________________
Under the terms of the Amendment, Advaxis and Penn have mutually agreed to eliminate an Advaxis milestone payment obligation to Penn and modify others relating to the development and commercialization of Advaxis’s Lm-LLO cancer immunotherapy technology.
Specifically, Advaxis and Penn agreed to eliminate the $400,000 milestone payment that Advaxis would be obligated to pay Penn upon the initiation of a Phase III clinical trial. Additionally, under the terms of the Agreement prior to this Amendment, a milestone payment of $600,000 would have been triggered upon the first regulatory approval for use in cancer or any other therapeutic indication, regardless of whether that approval was granted in the U.S. or in any other country. Pursuant to the terms of the Amendment, Advaxis and Penn modified this regulatory approval milestone event so that Advaxis will pay Penn only upon the first U.S or European regulatory approval and only for use in humans (not companion animals).
Further, under the terms of the Agreement prior to this Amendment, Advaxis would have been required to pay Penn a total of $2.5 million over a two year period upon the first commercial sale in any country and for any use, human or companion animals. Under the terms of the Amendment, Advaxis is only required to pay Penn such total amount with respect only to the first commercial sale in the U.S or European countries and with respect only to human (not companion animals) use.
In exchange, Advaxis agreed to increase the royalty rate by 1% that Advaxis will pay to Penn on annual net sales. Specifically, the royalty rate is increased from 1.5% to 2.5%. Should annual net sales reach $250 million or greater, the royalty rate will increase to 2.75%, but only with respect to those annual net sales in excess of $250 million. Additionally, Advaxis agreed to tiered sales milestone payments to Penn upon the achievement of cumulative global sales ranging between $250 million and $2 billion, so that the maximum aggregate amounts payable by Advaxis to Penn in the event that maximum sales milestones are achieved is $40 million.
|
|
|
Post by selluwud on Jul 29, 2014 13:36:50 GMT
The market likes, so far. Up this AM.
|
|